The PBAC may be unconcerned about some unimplemented recommendations but it could also 'remake' outcomes to make a listing possible, albeit after two years.
Could the 'review' process resolve disputes and not just rescind outcomes?
June 29, 2020 Latest News
Latest Video
New Stories
-
A good idea that will need to overcome an institutional mindset
February 19, 2025 - - Latest News -
Pharmaceuticals the latest Trump target for tariffs
February 19, 2025 - - Latest News -
IDT delivers strong first-half performance following strategic pivot
February 19, 2025 - - Latest News -
Montu announces two new appointments to leadership team
February 19, 2025 - - Latest News -
GBMA promotes prescribing shake-up to widen access and deliver savings
February 19, 2025 - - Latest News -
FDA grants fast-track designation for Neuren's NNZ-2591 in Pitt Hopkins syndrome
February 19, 2025 - - Australian Biotech -
Syntara’s topical anti-fibrotic drug leads to significant normalisation of skin in established scars
February 18, 2025 - - Australian Biotech